BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33024714)

  • 1. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models.
    Wang Q; Gavin W; Masiello N; Tran KB; Laible G; Shepherd PR
    Biotechnol Rep (Amst); 2020 Dec; 28():e00533. PubMed ID: 33024714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic goats producing an improved version of cetuximab in milk.
    Laible G; Cole S; Brophy B; Maclean P; How Chen L; Pollock DP; Cavacini L; Fournier N; De Romeuf C; Masiello NC; Gavin WG; Wells DN; Meade HM
    FASEB Bioadv; 2020 Nov; 2(11):638-652. PubMed ID: 33205005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why is there no biosimilar of Erbitux®?
    Douez E; D'Atri V; Guillarme D; Antier D; Guerriaud M; Beck A; Watier H; Foucault-Fruchard L
    J Pharm Biomed Anal; 2023 Sep; 234():115544. PubMed ID: 37418870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.
    Kang X; Zhou L; Jian YM; Lan SA; Xu F
    Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
    Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
    Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
    Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
    Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots.
    Lee J; Choi Y; Kim K; Hong S; Park HY; Lee T; Cheon GJ; Song R
    Bioconjug Chem; 2010 May; 21(5):940-6. PubMed ID: 20420360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.
    Luwor RB; Lu Y; Li X; Mendelsohn J; Fan Z
    Oncogene; 2005 Jun; 24(27):4433-41. PubMed ID: 15806152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.
    Ayoub D; Jabs W; Resemann A; Evers W; Evans C; Main L; Baessmann C; Wagner-Rousset E; Suckau D; Beck A
    MAbs; 2013; 5(5):699-710. PubMed ID: 23924801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
    Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
    Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.